Moderna, Inc. - NASDAQ:MRNA - Comprehensive analysis
Moderna's shares have experienced significant volatility, with investors initially overly optimistic in 2021 regarding the company's technological potential, followed by a more pessimistic outlook on its growth post-coronavirus. While we maintain modest expectations for sales of the firm's COVID vaccine due to the substantial demand driven by the pandemic in 2021 and 2022, we believe that Moderna's pipeline of mRNA-based vaccines and treatments is progressing rapidly across various therapeutic areas. Despite a decline in sales during 2023-2024 in anticipation of new product launches, we remain confident in the long-term sales trajectory of the company's diversified pipeline. We see strong validation of Moderna's technology in respiratory virus vaccines (with an RSV vaccine set to launch in 2024 and a COVID/flu combination vaccine expected in 2026), oncology (with a potential melanoma launch by 2027), and rare diseases (with accelerated approvals anticipated starting in 2027).
Free evaluation through quantitative algorithms Moderna, Inc. - NASDAQ:MRNA
Growth-Scoring Model Detail
Total Revenue Growth Over Prior Year | -52.75 | Market 1 Sector 5 |
Gross Profit Growth Over Prior Year | 0 | Market 0 Sector 0 |
EBITDA Growth Over Prior Year | 0 | Market 0 Sector 0 |
EBITA Growth Over Prior Year | 0 | Market 0 Sector 0 |
EBIT Growth Over Prior Year | 0 | Market 0 Sector 0 |
Earnings from Cont. Ops. Growth Over Prior Year | 0 | Market 0 Sector 0 |
Net Income Growth Over Prior Year | 0 | Market 0 Sector 0 |
Normalized Net Income Growth Over Prior Year | 0 | Market 0 Sector 0 |
Diluted EPS before Extra Growth Over Prior Year | 0 | Market 0 Sector 0 |
A/R Growth Over Prior Year | -59.87 | Market 1 Sector 5 |
Inventory Growth Over Prior Year | -42.08 | Market 1 Sector 2 |
PPE Net Growth Over Prior Year | 11.17 | Market 81 Sector 79 |
Total Assets Growth Over Prior Year | -23.25 | Market 2 Sector 18 |
Tangible Book Value Growth Over Prior Year | -21.43 | Market 8 Sector 31 |
Common Equity Growth Over Prior Year | -21.32 | Market 6 Sector 30 |
Cash from Ops. Growth Over Prior Year | 0 | Market 0 Sector 0 |
CAPEX Growth Over Prior Year | 48.7 | Market 94 Sector 85 |
Dividend per Share Growth Over Prior Year | 0 | Market 36 Sector 48 |
Levered Free Cash Flow Growth Over Prior Year | 0 | Market 0 Sector 0 |
Unlevered Free Cash Flow Growth Over Prior Year | 0 | Market 0 Sector 0 |
Profitability-Scoring Model Detail
Gross Margin % | -85.63 | Market 1 Sector 2 |
SG&A Margin % | 36.3 | Market 89 Sector 47 |
EBITDA Margin % | -116.07 | Market 1 Sector 6 |
EBITA Margin % | -121.91 | Market 1 Sector 6 |
EBIT Margin % | -121.91 | Market 1 Sector 7 |
Earnings from Cont. Ops Margin % | -110.04 | Market 1 Sector 8 |
Net Income Margin % | -110.04 | Market 1 Sector 8 |
Net Income Avail. for Common Margin % | -110.04 | Market 1 Sector 8 |
Normalized Net Income Margin % | -68.58 | Market 1 Sector 10 |
Levered Free Cash Flow Margin % | -95.41 | Market 1 Sector 10 |
Unlevered Free Cash Flow Margin % | -94.95 | Market 1 Sector 10 |
Return on Assets % | -15.14 | Market 1 Sector 48 |
Return on Capital % | -18.44 | Market 1 Sector 48 |
Return on Equity % | -28.77 | Market 2 Sector 56 |
Return on Common Equity % | -28.77 | Market 2 Sector 56 |
Total Asset Turnover | 0.2 | Market 18 Sector 42 |
